HK1152951A1 - Novel tumor marker - Google Patents
Novel tumor markerInfo
- Publication number
- HK1152951A1 HK1152951A1 HK11107164.2A HK11107164A HK1152951A1 HK 1152951 A1 HK1152951 A1 HK 1152951A1 HK 11107164 A HK11107164 A HK 11107164A HK 1152951 A1 HK1152951 A1 HK 1152951A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tumor marker
- novel tumor
- novel
- marker
- tumor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101587479A CN101942017B (zh) | 2009-07-07 | 2009-07-07 | 一种新的肿瘤标志物 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1152951A1 true HK1152951A1 (en) | 2012-03-16 |
Family
ID=43428800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11107164.2A HK1152951A1 (en) | 2009-07-07 | 2011-07-11 | Novel tumor marker |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2452948B1 (zh) |
CN (1) | CN101942017B (zh) |
AU (1) | AU2010268979B2 (zh) |
HK (1) | HK1152951A1 (zh) |
IL (2) | IL217276A (zh) |
RU (2) | RU2567005C2 (zh) |
SG (1) | SG177514A1 (zh) |
WO (1) | WO2011003369A1 (zh) |
ZA (1) | ZA201200888B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107095872A (zh) * | 2013-05-16 | 2017-08-29 | 国立大学法人京都大学 | 用于确定癌症预后的方法 |
JP6464156B2 (ja) * | 2013-06-27 | 2019-02-06 | 清華大学Tsinghua University | 腫瘍バイオマーカー |
CN105669836B (zh) * | 2014-11-20 | 2019-05-21 | 深圳市安群生物工程有限公司 | 人HSP90α-2抗原表位肽、抗原、抗体、应用及试剂盒 |
CN105646660B (zh) * | 2014-11-20 | 2019-05-24 | 深圳市安群生物工程有限公司 | 人HSP90α抗原表位肽、抗原、抗体、应用及试剂盒 |
CN105669834B (zh) * | 2014-11-20 | 2019-05-24 | 深圳市安群生物工程有限公司 | 人HSP90α-1抗原表位肽、抗原、抗体、应用及试剂盒 |
CN105753960B (zh) * | 2016-03-02 | 2019-06-07 | 苏州大学附属第一医院 | 一种肿瘤标志物及其应用 |
CN117388494A (zh) * | 2023-10-08 | 2024-01-12 | 烟台普罗吉生物科技发展有限公司 | 一种肿瘤标志物在肿瘤诊断及肿瘤治疗监测产品中的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000053169A2 (en) | 1999-03-12 | 2000-09-14 | The United States Of America, Represented By The Secretary Department Of Health And Human Services | Method of inhibiting a chaperone protein |
US6335157B1 (en) * | 1999-05-07 | 2002-01-01 | The European Molecular Biology Laboratory | Method based on localization of Hsp90 to the centrosome |
AU2001253140A1 (en) * | 2000-04-03 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Tumor markers in ovarian cancer |
DK1388734T3 (da) * | 2002-08-01 | 2004-05-03 | Mtm Lab Ag | Metode til opløsningsbaseret diagnose |
EP1457499A1 (en) * | 2003-03-12 | 2004-09-15 | Tufts University School Of Medicine | Inhibitors of extracellular Hsp90 |
US20050042681A1 (en) * | 2003-06-25 | 2005-02-24 | Van Eyk Jennifer E. | Methods and formulations for diagnosing, monitoring, staging and treating heart failure |
AU2005228899A1 (en) * | 2004-03-30 | 2005-10-13 | Novartis Vaccines And Diagnostics, Inc. | Substituted thiophene derivatives as anti-cancer agents |
JP4283812B2 (ja) * | 2006-01-06 | 2009-06-24 | 財団法人工業技術研究院 | 重症筋無力症の診断方法およびそのキット |
WO2008070472A2 (en) * | 2006-11-27 | 2008-06-12 | University Of Maryland, Baltimore | Use of plasma hsp90 related to malignancy |
BRPI0813002A2 (pt) * | 2007-06-29 | 2017-05-02 | Correlogic Systems Inc | marcadores preditivos para o câncer ovariano |
-
2009
- 2009-07-07 CN CN2009101587479A patent/CN101942017B/zh active Active
-
2010
- 2010-08-11 RU RU2012104024/10A patent/RU2567005C2/ru active
- 2010-08-11 WO PCT/CN2010/075896 patent/WO2011003369A1/zh active Application Filing
- 2010-08-11 SG SG2012000642A patent/SG177514A1/en unknown
- 2010-08-11 RU RU2015141408A patent/RU2714750C2/ru active
- 2010-08-11 EP EP10796746.5A patent/EP2452948B1/en active Active
- 2010-08-11 AU AU2010268979A patent/AU2010268979B2/en active Active
-
2011
- 2011-07-11 HK HK11107164.2A patent/HK1152951A1/xx unknown
- 2011-12-29 IL IL217276A patent/IL217276A/en active IP Right Grant
-
2012
- 2012-02-06 ZA ZA2012/00888A patent/ZA201200888B/en unknown
-
2017
- 2017-07-23 IL IL25361517A patent/IL253615B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
IL217276A (en) | 2017-07-31 |
EP2452948B1 (en) | 2019-03-06 |
RU2015141408A (ru) | 2018-12-26 |
SG177514A1 (en) | 2012-02-28 |
CN101942017A (zh) | 2011-01-12 |
RU2714750C2 (ru) | 2020-02-19 |
IL217276A0 (en) | 2012-02-29 |
WO2011003369A1 (zh) | 2011-01-13 |
AU2010268979A1 (en) | 2012-03-01 |
ZA201200888B (en) | 2019-09-25 |
EP2452948A4 (en) | 2013-04-17 |
RU2567005C2 (ru) | 2015-10-27 |
EP2452948A1 (en) | 2012-05-16 |
CN101942017B (zh) | 2013-08-14 |
IL253615A0 (en) | 2017-09-28 |
IL253615B (en) | 2019-11-28 |
AU2010268979B2 (en) | 2014-05-08 |
RU2012104024A (ru) | 2013-08-20 |
RU2015141408A3 (zh) | 2019-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2617730A4 (en) | IDENTIFICATION MARKER FOR LUNG CANCER | |
GB0907874D0 (en) | Skin marker | |
GB0717101D0 (en) | Tumour marker | |
GB0922437D0 (en) | Hypoxia tumour markers | |
GB201016139D0 (en) | Cancer phosholipidome | |
HK1256330A1 (zh) | 作為抗腫瘤響應提高的標記物的clever-1水平 | |
EP2399474A4 (en) | SHOE | |
HK1166130A1 (zh) | 作為癌症標誌物的應用 | |
PL2506733T3 (pl) | Podeszwa | |
EP2423683A4 (en) | MARKER FOR DENTISTRY DISEASES | |
EP2495561A4 (en) | MARKER FOR DETERMINING SENSITIVITY TO ANTICREMENT | |
EP2399877A4 (en) | FERRITE ON MN-ZN-CO BASE | |
EP2346531A4 (en) | TUMOR VACCINE | |
ZA201200888B (en) | New tumor marker | |
HK1140094A2 (en) | Shoe | |
GB0908071D0 (en) | Marker | |
GB2477687B (en) | X-ray marker | |
HK1165204A1 (zh) | 作為肺癌標誌物的 | |
GB0905964D0 (en) | Marker | |
GB0910751D0 (en) | Prostate cancer vaccine | |
GB2494830B (en) | Underwater marker | |
EP2290239A4 (en) | SHOE | |
GB2484732B (en) | Ground markers | |
GB201014687D0 (en) | Tile marker | |
EP2418490A4 (en) | TUMOR MARKERS AND USE THEREOF |